Contributed Presentations
1. 2'-Amino substituted MPTP depletes brain serotonin and norepinephrine without affecting dopamine in C57BL/6 mice. A. M. Andrews, N. A. Garrick and D. L. Murphy: 22nd Annual Meeting of the Society for Neuroscience, Anaheim, CA (1992).
2. Uptake inhibitors selectively attenuate depletions in cortical and hippocampal serotonin and norepinephrine caused by 2'-NH2-MPTP in two strains of mice. A. M. Andrews and D. L. Murphy: 23rd Annual Meeting of the Society for Neuroscience, Washington, DC (1993).
3. 2'-NH2-MPTP in Swiss Webster mice: Evidence for long term depletions in cortical and hippocampal serotonin and norepinephrine and differential protection by selective uptake inhibitors or monoamine oxidase inhibitors. A. M. Andrews and D. L. Murphy: 1993 Annual Meeting of the American College of Neuropsychopharmacology, Honolulu, HA (1993).
4. Acute neurotoxicity of 2'-NH2-MPTP: Changes in regional serotonin, 5-HIAA, norepinephrine, dopamine and GFAP levels in Swiss Webster mice. A. M. Andrews, D. B. Miller, J. P. O'Callaghan and D. L. Murphy: 25th Annual Meeting of the Society for Neuroscience, San Diego, CA (1995).
5. Transgenic mice with high levels of superoxide dismutase activity are protected from the neurotoxicity of 2'-NH2-MPTP on serotonin and norepinephrine nerve terminals. A. M. Andrews, B. Ladenheim, J. L. Cadet and D. L. Murphy: 26th Annual Meeting of the Society for Neuroscience, Washington, DC (1996).
6. 2'-NH2-MPTP selectively depletes cortical and hippocampal 5-HT and NE in the rat: A cross-species comparison versus MPTP and 2’-CH3-MPTP. A. M. Andrews, P. Mazzola-Pomietto and D. L. Murphy: 1996 Annual Meeting of the American College of Neuropsychopharmacology, San Juan, PR (1996).
7. Targeted disruption of the murine serotonin transporter gene. D. Bengel, D. L. Murphy, A. M. Andrews, D. Feltner, C. H. Wichems, M. Seemann, A. Heils, A. Grinberg, H. Westphal and K.-P. Lesch: 1996 Annual Meeting of the American College of Neuropsychopharmacology, San Juan, PR (1996).
8. 2'-NH2-MPTP selectively depletes cortical and hippocampal 5-HT and NE in the rat: A comparison with 2’-CH3-MPTP. A. M. Andrews, P. Mazzola-Pomietto and D. L. Murphy: 1997 Joint Meeting of the International Society for Neurochemistry and the American Society for Neurochemistry, Boston, MA (1997).
9. The effects of MDMA on monoamine neurotransmitter levels and core temperature in mice with a disrupted serotonin transporter. A. M. Andrews, C. H. Wichems, D. Bengel, K.-P. Lesch and D. L. Murphy: 27th Annual Meeting of the Society for Neuroscience, New Orleans, LA (1997).
10. A microdialysis study of the effects of high K+ and paroxetine on extracellular serotonin concentrations in serotonin transporter knock-out mice. A. M. Andrews, C. H. Wichems, Q. Li, A. Heils, K.-P. Lesch and D. L. Murphy: 28th Annual Meeting of the Society for Neuroscience, Los Angeles, CA (1998).
11. A microdialysis study of the effects of genetic inactivation of the serotonin transporter gene on baseline and K+-stimulated extracellular serotonin concentrations in mouse striatum. D. E. Fedele and A. M. Andrews: Proceedings of the 8th International Conference on In Vivo Methods, Stony Brook, NY (1999).
12. The effects of PCPA on monoamine neurotransmitter levels in mice with a disruption of the serotonin transporter gene. D. L. Sheridan, C. H. Wichems, D. L. Murphy, and A. M. Andrews: 29th Annual Meeting of the Society for Neuroscience, Miami, FL (1999).
13. Effects of serotonin transporter inactivation on extracellular 5-HT levels, in vivo microdialysis recovery, and MDMA-induced release of serotonin and dopamine in mouse striatum. T. A. Mathews, D. E. Fedele, E. L. Unger, K.-P. Lesch, D. L. Murphy and A. M. Andrews: 30th Annual Meeting of the Society for Neuroscience, New Orleans, LA (2000).
14. Binge-type behavior and brain serotonin. R. L. Corwin, S. F. Wagner, H. B. Rice and A. M. Andrews: 30th Annual Meeting of Society for Neuroscience, New Orleans, LA (2000).
15. Mechanisms mediating the increased anxiety-like and excess responses to stress in mice lacking the serotonin transporter. C. H. Wichems, Q. Li, A. Holmes, J. N. Crawley, O. Tjurmina, D. Goldstein, A. M. Andrews, K-. P. Lesch and D. L. Murphy: 30th Annual Meeting of the Society for Neuroscience, New Orleans, LA (2000).
16. 5-HT reuptake in SERT knockout mice by chronoamperometry. X. A. Perez and A. M. Andrews: Serotonin Club/Brain Research Bulletin Conference, New Orleans, LA (2000).
17. BDNF regulation of serotonin functioning and plasticity. L. A. Mamounas, C. A. Altar, A. M. Andrews and W. E. Lyons: Serotonin Club/Brain Research Bulletin Conference, New Orleans, LA (2000).
18. Quantitative microdialysis for serotonin in striatum and frontal cortex of genetically altered mice. D. E. Fedele, T. A. Mathews, L. A. Mamounas, W. E. Lyons and A. M. Andrews: Proceedings of the 9th International Conference on In Vivo Methods, Dublin, Ireland (2001).
19. Age-related changes in 5-HT immunocytochemistry in SERT knockout mice. A. M. Andrews, E. L. Unger, A. C. Chisnell, W. E. Lyons and L. A. Mamounas: 31st Annual Meeting of the Society for Neuroscience, San Diego, CA (2001).
20. Effects of 2’-NH2-MPTP in VMAT2 knockout mice. A. C. Chisnell, E. L. Unger, B. A. Fierst, D. L. Sheridan and A. M. Andrews: 31st Annual Meeting of the Society for Neuroscience, San Diego, CA (2001).
21. Quantitative microdialysis for sertotonin in BDNF knockout mice. T. A. Mathews, D. E. Fedele, L. A. Mamounas, W. E. Lyons and A. M. Andrews: 31st Annual Meeting of the Society for Neuroscience, San Diego, CA (2001).
22. Dopamine uptake in serotonin transporter knockout mice by chronoamperometry. X. A. Perez and A. M. Andrews: 31st Annual Meeting of the Society for Neuroscience, San Diego, CA (2001).
23. 5-HT, NE and BDNF levels in mice with pharmacologically or genetically-induced decreases in 5-HT uptake. M. E. Szapacs, C. M. McCann, E. L. Unger and A. M. Andrews: 31st Annual Meeting of the Society for Neuroscience, San Diego, CA (2001).
24. Cerebral amyloid deposition in APP/PS1 double transgenic mice is associated with induction of dystrophic serotonergic fibers. L. A. Mamounas, W. E. Lyons, O. Lee, W.-X. Li, W. Sterling, A. M. Andrews, E. L. Unger, A. C. Chisnell and M. K. Lee: 31st Annual Meeting of the Society for Neuroscience, San Diego, CA (2001).
25. Expression of human a-synuclein harboring the A53T, but not A30P, mutation leads to neurodegeneration in transgenic mice. M. K. Lee, W. Sterling, D. Eve, Y. Xu,, A. Mandir, T. Dawson V. Dawson A. M. Andrews and D. L. Price: 31st Annual Meeting of the Society for Neuroscience, San Diego, CA (2001).
26. Molecular mechanisms of cocaine reward: Combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. I. Sora, F. S. Hall, A. M. Andrews, M. Itokawa, X.-F. Li, H.-B Wei, H. Yamamoto, T. Yamamoto, K. Ikeda, C. Wichems, K.-P. Lesch, D. L. Murphy and G. R. Uhl: 31st Annual Meeting of the Society for Neuroscience, San Diego, CA (2001).
27. Synthesis of serotonin or dopamine coupled to solid support permitting interaction of all available functional groups. M. E. Szapacs, E. D. Horowitz, R. S. Bridges, P. C. Bevilacqua, R. L. Funk and A. M. Andrews: Gordon Research Conference on Bioanalytical Sensors, Ventura, CA (2002).
28. Adaptations in dopamine neurochemistry in SERT knockout mice by microdialysis and chronoamperometry. X. A. Perez, T. A. Mathews, A. C. Chisnell and A. M. Andrews: ACS 224th National Meeting and Exposition, Boston, MA (2002).
29. Decreased serotonin transporter expression prevents age-related serotonergic fiber loss in forebrain. E. L. Unger, O. Lee, W. E. Lyons, M. E. Blue, L. A. Mamounas and A. M. Andrews: World Alzheimer’s Congress, Stockholm, Sweden (2002).
30. A53T a-synuclein transgenic mice show preclinical motor abnormalities that precede the development of fatal motoric dysfunction. E. L. Unger, D. K. Reichenbach, M. K. Lee and A. M. Andrews: World Alzheimer’s Congress, Stockholm, Sweden (2002).
31. Regionally selective and progressive degeneration of the 5-HT system in a transgenic mouse model of AD. M. J. Yoo, W. Stirling, O. Lee, W. X. Li, M. E. Blue, A. M. Andrews, W. E. Lyons, L. A. Mamounas and M. K. Lee: World Alzheimer’s Congress, Stockholm, Sweden (2002).
32. Electroanalytical methodology elucidates changes in synaptic 5-HT caused by intermediate reductions in SERT expression. A. M. Andrews, T. A. Mathews and X. A. Perez: 32nd Annual Meeting of the Society for Neuroscience, Orlando, FL (2002).
33. RT-PCR analysis of BDNF mRNA in SERT knockout mice versus mice chronically treated with 5-HT reuptake inhibitors. K. J. Sowinski, M. E. Szapacs, C. M. McCann, E. L. Unger, D .J. Vandenberg and A. M. Andrews: 32nd Annual Meeting of the Society for Neuroscience, Orlando, FL (2002).
34. Degeneration of serotonin axons is accompanied by decreased 5-HT and increased BDNF in a transgenic mouse model of AD. A. L. Numis, M. E. Szapacs, M. K. Lee and A. M. Andrews: 32nd Annual Meeting of the Society for Neuroscience, Orlando, FL (2002).
35. Preclinical motor abnormalities in A53T a-synuclein transgenic mice are age-dependant. D. K. Reichenbach, E. L. Unger, W. X. Li, D. Eve, M. K. Lee and A. M. Andrews: 32nd Annual Meeting of the Society for Neuroscience, Orlando, FL (2002).
36. Decreased serotonin transporter expression prevents age-related serotonergic fiber loss in the forebrain. E. L. Unger, B. A. Luellen, O. Lee, W. E. Lyons, M. E. Blue, L. A. Mamounas and A. M. Andrews: 32nd Annual Meeting of Society for Neuroscience, Orlando, FL (2002).
37. The effect of serotonin axon degeneration on functional 5-HT neurotransmission and behavior. M. D. Aponte, D. K. Reichenbach, B. A. Luellen, T. A. Mathews and A. M. Andrews: 32nd Annual Meeting of the Society for Neuroscience, Orlando, FL (2002).
38. Basal extracellular and METH-induced striatal DA levels in SERT knockout mice. T. A. Mathews, E. L. Unger, A. C. Chisnell and A. M. Andrews: 32nd Annual Meeting of the Society for Neuroscience, Orlando, FL (2002).
39. Decreased serotonin transporter expression prevents age-related serotonergic fiber loss in the forebrain. E. L. Unger, B. A. Luellen, O. Lee, W. E. Lyons, M. E. Blue, L. A. Mamounas and A. M. Andrews: 35th Annual Winter Conference on Brain Research, Salt Lake City, UT (2003).
40. Electroanalytical methods elucidate the role of mutant a-synuclein in dopamine neurotransmission and Parkinson’s disease. X. A. Perez, T. A. Mathews, E. L. Unger, D. K. Reichenbach, M. K. Lee, A. M. Andrews: 2003 Pittsburgh Conference, Orlando, FL (2003).
41. Synthesis of serotonin or dopamine coupled to solid support permitting interaction of all available functional groups. M. E. Szapacs, E. D. Horowitz, R. S. Bridges, P. C. Bevilacqua, R. L. Funk, A. M. Andrews: 2003 Pittsburgh Conference, Orlando, FL (2003).
42. Serotonin and the fountain of youth: An examination of age-related serotonergic axon preservation versus serotonin levels in the forebrain of serotonin transporter knockout mice. A. L. Numis, E. L. Unger, B. A. Luellen, and A. M. Andrews: 2003 Undergraduate Exhibition, Pennsylvania State University, University Park, PA (2003).
43. Basal extracellular and METH-induced striatal DA levels in SERT knockout mice. T. A. Mathews, E. L. Unger, A. C. Chisnell and A. M. Andrews: 33rd Annual Meeting of the Society for Neuroscience, New Orleans, LA (2003).
44. BDNF levels in SERT knockout mice and their responsiveness to stress. M. E. Szapacs, A. McGraw, K. J. Sowinski and A. M. Andrews: 33rd Annual Meeting of the Society for Neuroscience, New Orleans, LA (2003).
45. Role of the vesicular monoamine transporter in the neurotoxic effects of 2’-NH2-MPTP in mice and rats. A. L. Numis and A. M. Andrews: 33rd Annual Meeting of the Society for Neuroscience, New Orleans, LA (2003).
46. Serotonin may be necessary for the astrocytic response to neuronal injury: Studies using 2’-NH2-MPTP. B. A. Luellen, A. L. Numis, D. L. Murphy, D. B. Miller, J. P. O’Callaghan, and A. M. Andrews: 33rd Annual Meeting of the Society for Neuroscience, New Orleans, LA (2003).
47. Quantitative microdialysis in BDNF knockout mice. L. A. Killingbeck, T. A. Mathews, W. E. Lyons, L. A. Mamounas and A. M. Andrews: 33rd Annual Meeting of the Society for Neuroscience, New Orleans, LA (2003).
48. Chronoamperometric Determination of Serotonin Transporter Function in Synaptosomes: Comparison with Traditional Radiochemical Methods. X. A. Perez, C. M. Squillante and A. M. Andrews: 2004 Pittsburgh Conference, Chicago, IL (2004).
49. The role of mitogen activated protein kinase pathways in age-related neuroprotection in serotonin transporter knockout mice. J. E. Cavanaugh, T. Smith, E. L. Unger, B. A. Luellen, A. M. Andrews and J. M. Lakoski: Serotonin Club Meeting, Porto, Portugal (2004).
50. Electroanalytical methodology elucidates changes in synaptic 5-HT caused by intermediate reductions in SERT expression. A. M. Andrews, T. A. Mathews and X. A. Perez: Serotonin Satellite Symposium of the 4th Meeting of the Federation of European Pharmacological Societies, Porto, Portugal (2004).
51. The role of increased extracellular serotonin in age-related changes in serotonergic and catecholaminergic forebrain innervation and astrocytic response. B. A. Luellen, W. E. Lyons, M. E. Blue, L. A. Mamounas and A. M. Andrews: Serotonin Satellite Symposium of the 4th Meeting of the Federation of European Pharmacological Societies, Porto, Portugal (2004).
52. Constitutive reductions in SERT expression alter age-dependent changes in serotonin innervation patterns. B. A. Luellen, E. L. Unger, W. E. Lyons, M. E. Blue, L. A. Mamounas and A. M. Andrews: 4th Meeting of the Federation of European Pharmacological Societies, Porto, Portugal (2004).